DiaSorin SpA
MIL:DIA

Watchlist Manager
DiaSorin SpA Logo
DiaSorin SpA
MIL:DIA
Watchlist
Price: 107.45 EUR 3.22% Market Closed
Market Cap: 5.7B EUR
Have any thoughts about
DiaSorin SpA?
Write Note

Gross Margin
DiaSorin SpA

64.8%
Current
66%
Average
47.2%
Industry

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
64.8%
=
Gross Profit
752.4m
/
Revenue
1.2B

Gross Margin Across Competitors

Country IT
Market Cap 5.7B EUR
Gross Margin
65%
Country US
Market Cap 204.9B USD
Gross Margin
56%
Country US
Market Cap 195.2B USD
Gross Margin
67%
Country US
Market Cap 146.7B USD
Gross Margin
64%
Country US
Market Cap 132.6B USD
Gross Margin
69%
Country IE
Market Cap 110.6B USD
Gross Margin
66%
Country US
Market Cap 64.7B USD
Gross Margin
45%
Country DE
Market Cap 55.6B EUR
Gross Margin
38%
Country CN
Market Cap 319.2B CNY
Gross Margin
65%
Country US
Market Cap 41.6B USD
Gross Margin
79%
Country US
Market Cap 37.7B USD
Gross Margin
41%
No Stocks Found

DiaSorin SpA
Glance View

Market Cap
5.7B EUR
Industry
Health Care

DiaSorin SpA is a prominent Italian diagnostic solutions provider that has carved a niche in the healthcare industry. Founded in 1968, the company specializes in developing and manufacturing innovative diagnostic tests that facilitate disease detection, monitoring, and prevention. With a robust portfolio that ranges from immunodiagnostics to molecular diagnostics, DiaSorin has made significant strides in addressing urgent healthcare needs. The company operates globally, serving hospitals and laboratories across numerous countries, and has established a strong commitment to research and development. This focus not only enhances their product offerings but also positions them as a key player in rapidly evolving sectors like infectious disease testing, oncology, and autoimmune disorders. For investors, DiaSorin presents an intriguing opportunity rooted in its strategic growth initiatives and resilience amid market challenges. The company's strong track record of revenue growth and profitability, coupled with its agile response to emerging health crises—such as the COVID-19 pandemic—highlights its operational efficiency and adaptability. Furthermore, with an ongoing emphasis on expanding its product lines and seeking partnerships to drive innovation, DiaSorin is well positioned to capitalize on the increasing demand for advanced diagnostic solutions. As healthcare continues to evolve with technological advances and personalized medicine, DiaSorin’s capabilities and strong market presence make it a compelling consideration for investors looking for sustainable growth in the life sciences sector.

DIA Intrinsic Value
92.61 EUR
Overvaluation 14%
Intrinsic Value
Price

See Also

Discover More
What is Gross Margin?

Gross Margin is the amount of money a company retains after incurring the direct costs associated with producing the goods it sells and the services it provides. The higher the gross margin, the more capital a company retains, which it can then use to pay other costs or satisfy debt obligations.

Gross Margin
64.8%
=
Gross Profit
752.4m
/
Revenue
1.2B
What is the Gross Margin of DiaSorin SpA?

Based on DiaSorin SpA's most recent financial statements, the company has Gross Margin of 64.8%.